Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 12, 1998, Pages 1547-1550

  Jung, Sang Hun ^a   Lee, Hui Soon ^a   Song, Jae Shin ^a   Kim, Hwan Mook ^b   Han, Sang Bae ^b   Lee, Chang Woo ^b   Lee, Moonsun ^c   Choi, Dong Rack ^c   Lee, Jung Ah ^c   Chung, Yong Ho ^c   Yoon, Sung June ^c   Moon, Eun Yi ^c   Hwang, Hyun Sook ^c   Seong, Seung Kyoo ^c   Lee, Dug Keun ^c  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c DongWha Pharm Ind Co   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DW 2143; IMIDAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; COLON CARCINOMA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CARCINOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; MICE; SULFONES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 18744432418     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00261-3     Document Type: Article

References (11)

1. 1. Jung, S.-H.; Song, J.-S.; Lee, H.-S.; Choi, S.-U.; Lee, C.-O. Bioorg. Med. Chem. Letters, 1996, 6, 2553-2558.
2. 2. Jung, S.-H.; Song, J.-S.; Lee, H.-S.; Choi, S.-U.; Lee, C.-O. Arch. Pharm. Res., 1996, 19, 570-580.
3. 3. Level of cytotoxicities of 1c is found in Table 1 as well as references 1 and 2.
4. 4. a) Houghton, P. J.; Houghton, J. A. Invest. New Drugs, 1996, 14, 271-280.
5. b) Howbert, J. J. Drug of Future, 1991, 16, 517-520. References therein.
6. 5. tumor growth inhibition of 1c; about 80% tumor suppression against murine mammary adenocarcinoma MM48 in C3H/He mice at dose of 300mg/kg/day × 5 per orally.
7. 6. Jung, S.-H.; Kwak, S.-J. Arch. Pharm. Res., 1997, 20, 283-287 and unpublished results.
8. 7. All compounds synthesized gave analytical and spectroscopical results consistent with the assigned structure.
9. 1,2)
10. 9. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monk, A.; Tierney, S.; Nofziger, T. M.; Seniff, D.; Boyd, M. R. Cancer Res. 1988, 48, 4827-4833.
11. 3, agents were administered on day 6, 8, 10, 12, and 14 after tumor transplantation. For NCI-H23 and SW620 human tumor xenograft models, agent 3b was orally administered on day 2, 4, 6, 8, 10, 12 after tumor transplantation and doxorubicin was intraperitonially administered everyday at the dose of 1mg/kg on day 2 to 11, 2mg/kg on day12 to 14, and 3mg/kg on day 15 to 18. Compound 3b (DW2143) was orally administered after dissolved in propylene glycol (Dose:100mg/kg/day × 2 and then 100mg/kg/2day × 4 for 3LL, 65mg/kg/2day × 5 for Colon26, 65mg/kg/2day × 6 for NCI-H23 and SW620). Doxorubicin was dissolved in sterilized saline prior to administration.